About Us

BELLUS Health is developing BLU-5937, a P2X3 inhibitor, to help people with chronic cough and other afferent hypersensitization-related disorders.

View More

Potential Benefits of High P2X3 Selectivity

Clinical trials have shown that inhibiting P2X3 receptors can effectively treat chronic cough. Unfortunately, a P2X3 inhibitor that has low selectivity has also been shown to adversely impact taste in a majority of patients. In a Phase 1 clinical trial, our highly-selective P2X3 inhibitor, BLU-5937, has been shown to produce little to no effect on taste.